News Related to ANVISA

Related coverage linked through entity extraction aliases.

Novo Nordisk Cuts GLP-1 Drug Prices Up to 50%; WADA Monitors Use, Brazil Reports 65 Deaths

Feb 25, 2026

Novo Nordisk will reduce prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting January 2027. Meanwhile, WADA investigates potential Olympic ban on weight loss drugs, and Brazil's Anvisa reports 65 suspected deaths linked to GLP-1 medications.

Amgen's Uplizna Wins FDA and European Approval for Generalized Myasthenia Gravis

Dec 11, 2025

Amgen received FDA and European Commission approval for Uplizna to treat generalized myasthenia gravis in adults who are anti-AChR or anti-MuSK antibody positive, offering twice-yearly maintenance dosing after initial loading doses.